Transactions on Additive Manufacturing Meets Medicine
Vol. 3 No. 1 (2021): Trans. AMMM
https://doi.org/10.18416/AMMM.2021.2109541

Scaffolds, Implants and Drug Delivery Systems, ID 541

The development of Hypromellose based semisolid 3D printing inks for drug delivery

Main Article Content

Bin Zhang (School of Pharmacy, University of East Anglia, Norwich, UK), Xinyi Teoh (School of Pharmacy, University of East Anglia, Norwich, UK and School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang, Malaysia), Peter Belton (School of Chemistry, University of East Anglia, Norwich, UK), Andy Gleadall (School of Mechanical, Loughborough University, Loughborough, UK), Richard Bibb (School of Design & Creative Arts, Loughborough University, Loughborough, UK), Sheng Qi (School of Pharmacy, University of East Anglia, Norwich, UK)

Copyright (c) 2021 Transactions on Additive Manufacturing Meets Medicine

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Abstract

3D printing is a promising method for producing medicines to tailored individual patient’s needs in the optimal dose and drug combinations which subsequently leads to enhanced therapeutic outcome. Here, we developed semisolid ink formulations based on hydroxypropyl methylcellulose (HPMC). We investigated the effects of additives including PVP and SiO2 and a model drug, paracetamol, on the HPMC ink rheology behaviour and shape fidelity when produced using semisolid 3D extrusion printing. The formulations were extruded from the printing nozzle and laminated layer-by-layer. The current study presents novel drug-loaded HPMC-based inks for 3D construct fabrication for potential drug delivery applications.

Article Details

How to Cite

Zhang, B., Teoh, X., Belton, P. ., Gleadall, A., Bibb, R., & Qi, S. (2021). The development of Hypromellose based semisolid 3D printing inks for drug delivery . Transactions on Additive Manufacturing Meets Medicine, 3(1), 541. https://doi.org/10.18416/AMMM.2021.2109541